Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
NCT06435468
Autoimmune Diseases, Autoinflammatory Disease
Bron, France
View Trial DetailsNCT Number: NCT07040774
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.
Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.
In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.
The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.
The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Interested in participating?
Request InfoAll sexes
Observational
Medical University Innsbruck, Innsbruck, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2025-2045
Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.
Time frame: 2025-2045
Description of specific immunological factors according to genotype
Time frame: 2025-2045
Biomarkers identified for diagnosis, prognosis and monitoring of disease activity
Time frame: 2025-2045
Treatment response by phenotype and genotype
Contact information is provided by the study sponsor or research team.
Imagine Institute
Other
Acronym: EU-IFNp
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06435468
Autoimmune Diseases, Autoinflammatory Disease
Bron, France
View Trial DetailsNCT05432349
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT06504433
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Disease
Randwick, New South Wales, Australia
View Trial DetailsNCT06048523
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Disease
Bordeaux, France
View Trial Details